查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
降血脂药物市场：依药物类别、按地区：市场规模、份额、前景、机会分析，2023-2030
市场调查报告书
商品编码
1330165

降血脂药物市场：依药物类别、按地区：市场规模、份额、前景、机会分析，2023-2030

Antihyperlipidemic Drugs Market, By Drug Class, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格
简介目录

高血脂症包括各种遗传性疾病和后天性疾病，这些疾病会增加血液中胆固醇和三酸甘油酯等脂质的浓度，从而增加心臟病和中风的风险，而心臟病和中风是全球范围内导致死亡的主要原因。这是一个术语。 由于高血脂非常常见，因此世界各地对有助于降低高血脂和心血管疾病风险的降血脂药物的需求不断增长。

市场动态：

高脂血症盛行率的增加、久坐生活方式的迅速增加、老年人口的增加、降血脂药物需求的增加以及新药的推出正在导致世界范围内降血脂人数的上升。这些是预计将增加成长的主要因素的药品市场。

例如，根据美国中风协会的数据，中风是美国第五大死因和导致残疾的主要原因。 美国每年有超过 795,000 人中风。 其中约 61 万名患者患有首次或新发中风。

此外，根据《美国心臟协会杂誌》重新提交的报告，在欧洲，中风是最常见的死亡原因，也是成人残疾的主要原因。 欧洲中风行动计画 (SAP-E) 是一个泛欧洲项目，设定了到 2030 年基于证据的预防行动和中风服务的实施目标。

本研究的主要特点

  • 本报告对全球降血脂药物市场进行了详细分析，并以2022年为基准年估算了预测期（2023-2030年）的市场规模和年均增长率（CAGR%）。
  • 它也揭示了各个细分市场的潜在收入机会，并为该市场提供了一系列有吸引力的投资建议。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景、主要参与者采取的竞争策略等的重要见解。
  • 根据以下参数对全球降血脂药物市场的主要参与者进行了分析，例如公司亮点、产品组合、主要亮点、绩效和策略。
  • 本研究涵盖的主要公司包括赛诺菲 S.A.、辉瑞公司、Mylan N.V、安进公司、艾伯维公司、默克公司、雷迪博士实验室有限公司、百时美施贵宝公司、阿斯利康有限公司和第一三共有限公司等。
  • 此报告的见解使行销人员和公司主管能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 《全球降血脂药物市场报告》是针对该产业的各个利害关係人，例如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 利害关係人可以透过用于分析全球降血脂药物市场的各种策略矩阵来促进决策。

目录

第1章研究目的与前提

  • 研究目的
  • 先决条件
  • 缩写

第2章市场概述

  • 报告摘要
    • 市场定义和范围
  • 执行摘要
  • 连贯的机会地图 (COM)

第3章市场动态、法规与趋势分析

  • 市场动态
    • 全球高血脂症盛行率不断上升
    • 治疗费用高且缺乏认识
    • 降血脂药物的需求不断增加
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 合併/收购场景

第 4 章全球降血脂药物市场 - 冠状病毒 (COVID-19) 大流行的影响

  • COVID-19 的流行病学
  • 供给面与需求面分析
  • 经济影响

第5章全球降血脂药物市场：依药物类别划分，2023-2030

  • 他汀类药物
  • 胆汁酸分泌抑制剂
  • 胆固醇吸收抑制剂
  • 原纤维酸衍生物
  • PCSK9抑制剂
  • 复方药物
  • 其他

第6章全球降血脂药市场：依地区划分，2023-2030

  • 北美
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第7章竞争态势

  • Sanofi S.A.
  • Pfizer Inc.
  • Mylan N.V.
  • Amgen Inc.
  • Abbvie Inc.
  • Merck & Co., Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • Daiichi Sankyo Company

第 8 章部分

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5992

Hyperlipidemia is a term that encompasses various genetic and acquired disorders that describe an elevated lipid levels, such as cholesterol and triglycerides, in the blood, which in turn increases the risk of heart disease and stroke, the leading cause of death worldwide. It is a very common disorder, and thus, there is an increasing demand for antihyperlipidemic drugs across the world, as they help reduce the risk of hyperlipidemia and cardiovascular diseases.

Market Dynamics:

Increasing prevalence of hyperlipidemia, surge in sedentary lifestyle, growing geriatric population, increasing demand for antihyperlipidemic drugs, and introduction of novel drugs are major factors expected to augment the growth of the global antihyperlipidemic drugs market.

For instance, according to the American Stroke Association, stroke is the No. 5 cause of death and a leading cause of disability in the United States. Every year, more than 795,000 people in the U.S. have a stroke. About 610,000 of these are first or new strokes.

Moreover, according to the repost by AHA Journals, in Europe, stroke is the most common cause of death as well as a leading cause of adult disability. The Stroke Action Plan for Europe (SAP-E) is a pan-European project that sets targets for the implementation of an evidence-based preventive actions and stroke services until 2030.

Key features of the study:

  • This report provides in-depth analysis of the global antihyperlipidemic drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global antihyperlipidemic drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company, Limited, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global antihyperlipidemic drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antihyperlipidemic drugs market.

Detailed Segmentation:

  • Global Antihyperlipidemic Drugs Market, By Drug Class:
    • Statins
    • Bile Acid Sequestrants
    • Cholesterol Absorption Inhibitors
    • Fibric Acid Derivatives
    • PCSK9 Inhibitors
    • Combination
    • Others
  • Global Antihyperlipidemic Drugs Market, By Geography:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Sanofi S.A.
    • Pfizer Inc.
    • Mylan N.V.
    • Amgen Inc.
    • Abbvie Inc.
    • Merck & Co., Inc.
    • Reddy's Laboratories Ltd.
    • Bristol-Myers Squibb Company
    • AstraZeneca plc
    • Daiichi Sankyo Company, Limited, among others.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing prevalence of hyperlipidemia worldwide
    • High cost of treatment and lack of awareness
    • Increasing demand for antihyperlipidemic drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Antihyperlipidemic Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Antihyperlipidemic Drugs Market, By Drug Class, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • Statins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Bile Acid Sequestrants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Cholesterol Absorption Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Fibric Acid Derivatives
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • PCSK9 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Combination
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)

6. Global Antihyperlipidemic Drugs Market, By Region, 2023-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2023-2030,(US$ Bn)

7. Competitive Landscape

  • Sanofi S.A.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbvie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr. Reddy's Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Daiichi Sankyo Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

8. Section

  • Research Methodology
  • About us